Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation

Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

(2016) Angelica Loskog et al.   BRITISH JOURNAL OF CANCER

Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection

(2016) Eugene A Zhukovsky et al.   CURRENT OPINION IN IMMUNOLOGY

Immunocytokines for cancer treatment: past, present and future

(2016) Dario Neri et al.   CURRENT OPINION IN IMMUNOLOGY

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site

(2016) Jonathan D. Kiefer et al.   IMMUNOLOGICAL REVIEWS

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Blinatumomab: First Global Approval

(2015) Mark Sanford   DRUGS

Metabolic reprogramming: the emerging concept and associated therapeutic strategies

(2015) Go J. Yoshida   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf

(2015) Linda Hammerich et al.   Molecular Oncology

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

(2015) Emanuela Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS

(2015) Miguel F. Sanmamed et al.   SEMINARS IN ONCOLOGY

In-situ tumor vaccination: Bringing the fight to the tumor

(2015) Robert H Pierce et al.   Human Vaccines & Immunotherapeutics

Kick-starting the cancer-immunity cycle by targeting CD40

(2015) P Ellmark et al.   OncoImmunology

Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma

(2014) Paolo A. Ascierto   CANCER IMMUNOLOGY IMMUNOTHERAPY

Armed antibodies for cancer treatment: a promising tool in a changing era

(2014) Riccardo Danielli et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell-Dependent Tumor Immunity

(2014) S. M. Mangsbo et al.   CLINICAL CANCER RESEARCH

Probody therapeutics for targeting antibodies to diseased tissue

(2014) Krishna R Polu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer

(2014) Marieke F. Fransen et al.   VACCINE

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

(2014) Linda C Sandin et al.   OncoImmunology

Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects

(2013) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

Agonistic CD40 Antibodies and Cancer Therapy

(2013) R. H. Vonderheide et al.   CLINICAL CANCER RESEARCH

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

(2013) Aurélien Marabelle et al.   JOURNAL OF CLINICAL INVESTIGATION

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Treatment Efficacy and Immune Stimulation by AdCD40L Gene Therapy of Spontaneous Canine Malignant Melanoma

(2013) Sara Westberg et al.   JOURNAL OF IMMUNOTHERAPY

Antitumor activities of agonistic anti-TNFR antibodies require differential Fc RIIB coengagement in vivo

(2013) F. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer

(2013) L. C. Sandin et al.   Cancer Immunology Research

Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles

(2012) Sissela Broos et al.   BIOMATERIALS

Combination of a Bispecific Antibody and Costimulatory Antibody-Ligand Fusion Proteins for Targeted Cancer Immunotherapy

(2012) Nora Hornig et al.   JOURNAL OF IMMUNOTHERAPY

The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy

(2012) Asís Palazón et al.   Cancer Discovery

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study

(2011) Y. H. Kim et al.   BLOOD

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

(2011) Nicholas S. Wilson et al.   CANCER CELL

Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody

(2011) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

(2011) A. L. White et al.   JOURNAL OF IMMUNOLOGY

A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors

(2010) M. J. Goldstein et al.   BLOOD

AdCD40L Immunogene Therapy for Bladder Carcinoma--The First Phase I/IIa Trial

(2010) P.-U. Malmstrom et al.   CLINICAL CANCER RESEARCH

Efficient Adenovector CD40 Ligand Immunotherapy of Canine Malignant Melanoma

(2009) Henrik von Euler et al.   JOURNAL OF IMMUNOTHERAPY

Local AdCD40L Gene Therapy is Effective for Disseminated Murine Experimental Cancer by Breaking T-cell Tolerance and Inducing Tumor Cell Growth Inhibition

(2009) Camilla Lindqvist et al.   JOURNAL OF IMMUNOTHERAPY

Deliberately provoking local inflammation drives tumors to become their own protective vaccine site

(2008) Connie Jackaman et al.   INTERNATIONAL IMMUNOLOGY

A Novel Antibody–4-1BBL Fusion Protein for Targeted Costimulation in Cancer Immunotherapy

(2008) Dafne Müller et al.   JOURNAL OF IMMUNOTHERAPY